Sodium channel inhibitors

US11932673B2 · kind B2 · utility

Assignee

• MAXION THERAPEUTICS LIMITED · GB

Inventors

• Aneesh Karatt Vellatt · Pidley, GB
• John McCafferty · Babraham, GB
• Sachin Surade · Hornsby, AU
• Tim Luetkens · Salt Lake City, US
• Edward William Masters · Pidley, GB
• Michael Dyson · Cambridge, GB
• Damian Colin Bell · Pidley, GB

Key dates

• Filing date: Jul 11, 2018
• Grant date: Mar 19, 2024
• Expiry date: Feb 21, 2039

Classification

• Technology area (CPC C): Chemistry; Metallurgy
• CPC primary: C07K2319/30
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

Binding members for sodium channel Nav1.7 and their use in medicine including for treatment of pain or epilepsy. Binding members comprise a fusion protein containing a Nav1.7-binding peptide, e.g., venom toxin peptide or knottin (“donor diversity scaffold domain”) inserted within an antibody variable domain (“recipient diversity scaffold domain”), and a partner domain (e.g., antibody variable domain), optionally wherein the partner domain enhances specificity of binding to Nav1.7 over other sodium channels.